{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T06:01:13Z","timestamp":1780898473869,"version":"3.54.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"vor","delay-in-days":54,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-026-16037-8","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T05:47:18Z","timestamp":1776232038000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prognostic value of PSA Kinetic Ratio in high-volume mCSPC patients treated with abiraterone or enzalutamide: a single-center retrospective study"],"prefix":"10.1186","volume":"26","author":[{"given":"Sila","family":"Oksuz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oguzcan","family":"K\u0131n\u0131koglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nisanur","family":"Sariyar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mert","family":"Ozdemir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deniz","family":"Isik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heves","family":"Surmeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seval","family":"Ay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hatice","family":"Odabas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nedim","family":"Turan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,15]]},"reference":[{"key":"16037_CR1","doi-asserted-by":"publisher","unstructured":"Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, \u00d6zg\u00fcro\u011flu M, Ye D, Feyerabend S, Protheroe A, De Porre P, Kheoh T, Park YC, Todd MB, Chi KN. LATITUDE Investigators. Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer. N Engl J Med. 2017;377(4):352\u2013360. https:\/\/doi.org\/10.1056\/NEJMoa1704174. Epub 2017 Jun 4. PMID: 28578607.","DOI":"10.1056\/NEJMoa1704174"},{"issue":"2","key":"16037_CR2","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1056\/NEJMoa1903835","volume":"381","author":"ID Davis","year":"2019","unstructured":"Davis ID, Martin AJ, Stockler MR, Begbie S, Chi KN, Chowdhury S, Coskinas X, Frydenberg M, Hague WE, Horvath LG, Joshua AM, Lawrence NJ, Marx G, McCaffrey J, McDermott R, McJannett M, North SA, Parnis F, Parulekar W, Pook DW, Reaume MN, Sandhu SK, Tan A, Tan TH, Thomson A, Tu E, Vera-Badillo F, Williams SG, Yip S, Zhang AY, Zielinski RR, Sweeney CJ. ENZAMET Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group. Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer. N Engl J Med. 2019;381(2):121\u201331. https:\/\/doi.org\/10.1056\/NEJMoa1903835. Epub 2019 Jun 2. PMID: 31157964.","journal-title":"N Engl J Med"},{"key":"16037_CR3","doi-asserted-by":"crossref","unstructured":"Rehman Y, Rosenberg JE. Abiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer. Drug Des Devel Ther. 2012;6:13\u2009\u2013\u20098. doi: 10.2147\/DDDT.S15850. Epub 2012 Jan 16. PMID: 22291466; PMCID: PMC3267518.","DOI":"10.2147\/DDDT.S15850"},{"issue":"3","key":"16037_CR4","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/S0090-4295(02)01593-5","volume":"60","author":"SP Balk","year":"2002","unstructured":"Balk SP. Androgen receptor as a target in androgen-independent prostate cancer. Urology. 2002;60(3):132\u20138.","journal-title":"Urology"},{"issue":"5928","key":"16037_CR5","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1126\/science.1168175","volume":"324","author":"C Tran","year":"2009","unstructured":"Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, Wongvipat J, Smith-Jones PM, Yoo D, Kwon A, Wasielewska T, Welsbie D, Chen CD, Higano CS, Beer TM, Hung DT, Scher HI, Jung ME, Sawyers CL. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science. 2009;324(5928):787\u201390. https:\/\/doi.org\/10.1126\/science.1168175. Epub 2009 Apr 9. PMID: 19359544; PMCID: PMC2981508.","journal-title":"Science"},{"issue":"4","key":"16037_CR6","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1177\/1756287212452196","volume":"4","author":"MT Schweizer","year":"2012","unstructured":"Schweizer MT, Antonarakis ES. Abiraterone and other novel androgen-directed strategies for the treatment of prostate cancer: a new era of hormonal therapies is born. Ther Adv Urol. 2012;4(4):167\u201378. PMID: 22852027; PMCID: PMC3398601.","journal-title":"Ther Adv Urol"},{"key":"16037_CR7","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/pcan.2013.41","volume":"17","author":"O Goodman","year":"2014","unstructured":"Goodman O, Flaig T, Molina A, et al. Exploratory analysis of the visceral disease subgroup in a phase III study of abiraterone acetate in metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2014;17:34\u20139. https:\/\/doi.org\/10.1038\/pcan.2013.41.","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"36","key":"16037_CR8","doi-asserted-by":"publisher","first-page":"e7823","DOI":"10.1097\/MD.0000000000007823","volume":"96","author":"G Ji","year":"2017","unstructured":"Ji G, Song G, Huang C, He S, Zhou L. Rapidly decreasing level of prostate-specific antigen during initial androgen deprivation therapy is a risk factor for early progression to castration-resistant prostate cancer: a retrospective study. Medicine. 2017;96(36):e7823.","journal-title":"Medicine"},{"key":"16037_CR9","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1186\/s13104-021-05641-5","volume":"14","author":"S Nakanishi","year":"2021","unstructured":"Nakanishi S, Goya M, Tamaki M, et al. Three-month early change in prostate-specific antigen levels as a predictive marker for overall survival during hormonal therapy for metastatic hormone-sensitive prostate cancer. BMC Res Notes. 2021;14:227. https:\/\/doi.org\/10.1186\/s13104-021-05641-5.","journal-title":"BMC Res Notes"},{"issue":"1","key":"16037_CR10","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s12894-018-0353-4","volume":"18","author":"H Sato","year":"2018","unstructured":"Sato H, Narita S, Tsuchiya N, Koizumi A, Nara T, Kanda S, et al. Impact of early changes in serum biomarkers following androgen deprivation therapy on clinical outcomes in metastatic hormone-sensitive prostate cancer. BMC Urol. 2018;18(1):32.","journal-title":"BMC Urol"},{"issue":"1","key":"16037_CR11","doi-asserted-by":"publisher","first-page":"386","DOI":"10.3390\/jcm15010386","volume":"15","author":"U Ozkerim","year":"2026","unstructured":"Ozkerim U, Kinikoglu O, Isik D, Altintas YE, Ay Ersoy S, Surmeli H, Odabas H, Basoglu T, Turan N. Association Between Time to PSA Nadir, Radiologic Progression, and PSA Progression in mHSPC Patients Treated with Abiraterone or Enzalutamide. J Clin Med. 2026;15(1):386. https:\/\/doi.org\/10.3390\/jcm15010386.","journal-title":"J Clin Med"},{"issue":"9","key":"16037_CR12","doi-asserted-by":"publisher","first-page":"607","DOI":"10.4111\/kju.2012.53.9.607","volume":"53","author":"SY Hong","year":"2012","unstructured":"Hong SY, Cho DS, Kim SI, Ahn HS, Kim SJ. Prostate-specific antigen nadir and time to prostate-specific antigen nadir following maximal androgen blockade independently predict prognosis in patients with metastatic prostate cancer. Korean J Urol. 2012;53(9):607\u201313. https:\/\/doi.org\/10.4111\/kju.2012.53.9.607. Epub 2012 Sep 19. PMID: 23060997; PMCID: PMC3460002.","journal-title":"Korean J Urol"},{"key":"16037_CR13","doi-asserted-by":"publisher","unstructured":"Huang SP, Bao BY, Wu MT, Choueiri TK, Goggins WB, Huang CY, Pu YS, Yu CC, Huang CH. Impact of prostate-specific antigen (PSA) nadir and time to PSA nadir on disease progression in prostate cancer treated with androgen-deprivation therapy. Prostate. 2011;71(11):1189-97. https:\/\/doi.org\/10.1002\/pros.21334. Epub 2011 Jan 12. PMID: 21656829.","DOI":"10.1002\/pros.21334"},{"issue":"17","key":"16037_CR14","doi-asserted-by":"publisher","first-page":"4625","DOI":"10.1158\/1078-0432.CCR-20-0054","volume":"26","author":"B You","year":"2020","unstructured":"You B, Robelin P, Tod M, Louvet C, Lotz JP, Abadie-Lacourtoisie S, Fabbro M, Desauw C, Bonichon-Lamichhane N, Kurtz JE, Follana P, Leheurteur M, Piano FD, Ferron G, De Rauglaudre G, Ray-Coquard I, Combe P, Chevalier-Place A, Joly F, Leary A, Pujade-Lauraine E, Freyer G, Colomban O. CA-125 ELIMination Rate Constant K (KELIM) Is a Marker of Chemosensitivity in Patients with Ovarian Cancer: Results from the Phase II CHIVA Trial. Clin Cancer Res. 2020;26(17):4625\u201332. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-0054. Epub 2020 Mar 24. PMID: 32209570.","journal-title":"Clin Cancer Res"},{"key":"16037_CR15","doi-asserted-by":"publisher","unstructured":"Bouvarel B, Colomban O, Frenel JS, Loaec C, Bourgin C, Berton D, Freyer G, You B, Classe JM. Clinical impact of CA-125 ELIMination rate constant K (KELIM) on surgical strategy in advanced serous ovarian cancer patients. Int J Gynecol Cancer. 2024;34(4):574\u2013580. https:\/\/doi.org\/10.1136\/ijgc-2023-004872. PMID: 38242546.","DOI":"10.1136\/ijgc-2023-004872"},{"key":"16037_CR16","first-page":"e2300208","volume":"8","author":"A Carrot","year":"2024","unstructured":"Carrot A, Oudard S, Colomban O, Fizazi K, Maillet D, Sartor O, Freyer G, You B. Prognostic Value of the Modeled Prostate-Specific Antigen KELIM Confirmation in Metastatic Castration-Resistant Prostate Cancer Treated With Taxanes in FIRSTANA. JCO Clin Cancer Inf. 2024;8:e2300208. PMID: 38364191; PMCID: PMC10883629.","journal-title":"JCO Clin Cancer Inf"},{"key":"16037_CR17","doi-asserted-by":"publisher","first-page":"S666","DOI":"10.1016\/j.annonc.2021.08.1147","volume":"32","author":"A Carrot","year":"2021","unstructured":"Carrot A, Elaidi RT, Colomban O, et al. 634P Prognostic value of the modeled PSA kinetic parameter (KELIM) in prostate cancer patients with rising PSA after primary local therapy treated in a prospective phase III trial with ADT +\/- docetaxel. Ann Oncol. 2021;32:S666.","journal-title":"Ann Oncol"},{"key":"16037_CR18","doi-asserted-by":"publisher","unstructured":"Hussain M, Tangen CM, Higano C, Schelhammer PF, Faulkner J, Crawford ED, Wilding G, Akdas A, Small EJ, Donnelly B, MacVicar G, Raghavan D, Southwest Oncology Group Trial 9346 (INT-0162). Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). J Clin Oncol. 2006;24(24):3984-90. https:\/\/doi.org\/10.1200\/JCO.2006.06.4246. PMID: 16921051.","DOI":"10.1200\/JCO.2006.06.4246"},{"issue":"1","key":"16037_CR19","doi-asserted-by":"publisher","first-page":"12071","DOI":"10.1038\/s41598-019-48600-8","volume":"9","author":"S Narita","year":"2019","unstructured":"Narita S, Nomura K, Hatakeyama S, Takahashi M, Sakurai T, Kawamura S, Hoshi S, Ishida M, Kawaguchi T, Ishidoya S, Shimoda J, Sato H, Mitsuzuka K, Tochigi T, Tsuchiya N, Ohyama C, Arai Y, Nagashima K, Habuchi T. Prognostic significance of early changes in serum biomarker levels in patients with newly diagnosed metastatic prostate cancer. Sci Rep. 2019;9(1):12071. https:\/\/doi.org\/10.1038\/s41598-019-48600-8. PMID: 31427687; PMCID: PMC6700107.","journal-title":"Sci Rep"},{"issue":"9","key":"16037_CR20","doi-asserted-by":"publisher","first-page":"e14014","DOI":"10.1111\/eci.14014","volume":"53","author":"L Giovanella","year":"2023","unstructured":"Giovanella L, Garo ML, Cuzzocrea M, Paone G, Herrmann K. Prognostic role of early prostate specific antigen changes after [177 Lu]Lu-PSMA radioligand therapy of metastasized prostate cancer: A meta-analysis. Eur J Clin Invest. 2023;53(9):e14014. https:\/\/doi.org\/10.1111\/eci.14014. Epub 2023 May 17. PMID: 37194605.","journal-title":"Eur J Clin Invest"},{"key":"16037_CR21","doi-asserted-by":"publisher","unstructured":"Liu HD, Wu HL, Ma LL, Cui Y, Wang SW, Shen GH. [Application of CA125 elimination rate constant K score in prognostic forecast of patients undergoing interval debulking surgery for high grade serous ovarian cancer]. Zhonghua Fu Chan Ke Za Zhi. 2025;60(6):461\u2013468. Chinese. https:\/\/doi.org\/10.3760\/cma.j.cn112141-20250102-00001. PMID: 40582969.","DOI":"10.3760\/cma.j.cn112141-20250102-00001"},{"issue":"2","key":"16037_CR22","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.ygyno.2013.05.013","volume":"130","author":"B You","year":"2013","unstructured":"You B, Colomban O, Heywood M, Lee C, Davy M, Reed N, Pignata S, Varsellona N, Emons G, Rehman K, Steffensen KD, Reinthaller A, Pujade-Lauraine E, Oza A. The strong prognostic value of KELIM, a model-based parameter from CA 125 kinetics in ovarian cancer: data from CALYPSO trial (a GINECO-GCIG study). Gynecol Oncol. 2013;130(2):289\u201394. https:\/\/doi.org\/10.1016\/j.ygyno.2013.05.013. Epub 2013 May 18. PMID: 23694718.","journal-title":"Gynecol Oncol"},{"issue":"17","key":"16037_CR23","doi-asserted-by":"publisher","first-page":"3251","DOI":"10.1002\/cam4.4685","volume":"11","author":"Z Zhenhao","year":"2022","unstructured":"Zhenhao Z, Xiaofeng C, Hao J, Ming Y, Hongtao Z, Wenrui H, Cheng Z, Xiaochen Z, Gongxian W. The slope associated with nadir prostate-specific antigen is prognostically significant in men with hormone-sensitive prostate cancer after primary androgen deprivation therapy. Cancer Med. 2022;11(17):3251\u20139. Epub 2022 Mar 21. PMID: 35307955; PMCID: PMC9468434.","journal-title":"Cancer Med"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-16037-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16037-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16037-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T05:56:12Z","timestamp":1780898172000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-16037-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,15]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["16037"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-16037-8","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,15]]},"assertion":[{"value":"2 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"728"}}